Sigalotti Luca, Fratta Elisabetta, Parisi Giulia, Coral Sandra, Maio Michele
Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy.
Methods Mol Biol. 2014;1102:481-99. doi: 10.1007/978-1-62703-727-3_25.
Prognostic molecular markers are urgently needed for allowing to discriminate the clinical course of disease of melanoma patients, which is highly heterogeneous and unpredictable also within a specific clinicopathological stage and substage of disease. Alterations in DNA methylation have been reported to be widely present in cutaneous melanoma, profoundly impacting its biology. In line with this notion, we have identified methylation markers as independent prognostic factors in stage IIIC melanoma patients. In this chapter we describe the measurement of the methylation of the Long Interspersed Nucleotide Element-1 sequences in laser capture microdissected tumor tissues as a prognostic tool in stage III melanoma patients, which could help in achieving a more appropriate and patient-tailored clinical management of cutaneous melanoma.
迫切需要预后分子标志物来区分黑色素瘤患者的疾病临床进程，该疾病具有高度异质性，即使在特定的临床病理分期和疾病亚分期内也难以预测。据报道，DNA甲基化改变广泛存在于皮肤黑色素瘤中，对其生物学特性有深远影响。基于这一观点，我们已确定甲基化标志物是IIIC期黑色素瘤患者的独立预后因素。在本章中，我们描述了在激光捕获显微切割的肿瘤组织中测量长散在核元件-1序列的甲基化，作为III期黑色素瘤患者的一种预后工具，这有助于实现对皮肤黑色素瘤更恰当的、针对患者的临床管理。
